CGON
CG Oncology, Inc. Common stock
1W: +1.2%
1M: +15.3%
3M: +74.1%
YTD: +55.7%
1Y: +132.1%
$65.08
-0.78 (-1.18%)
After Hours: $66.34 (+1.26, +1.94%)
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Moderate
50
Insider+$0.9M
Congress—
ETF Holdings—
Key Statistics
Market Cap$5.5B
52W Range14.8-69.35
Volume2,553,967
Avg Volume1,248,096
Beta1.19
Dividend—
Analyst Ratings
Company Info
CEOArthur Kuan
Employees113
SectorHealthcare
IndustryBiotechnology
IPO Date2024-01-25
Websitecgoncology.com
400 Spectrum Center Drive
Irvine, DE
US
Irvine, DE
US
About CG Oncology, Inc. Common stock
CG Oncology Inc is a clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. Their product candidate cretostimogene, is initially in clinical development for the treatment of patients with high-risk Non-Muscle Invasive Bladder Cancer who are unresponsive to Bacillus Calmette Guerin (BCG) therapy, the current standard-of-care for high-risk NMIBC.
Latest News
This Biotech Stock Up 135% Just Faced a $44 Million Trim. Here's What Investors Should Know
Boothbay Fund Management LLC Has $3.81 Million Stock Holdings in CG Oncology, Inc. $CGON
ArrowMark Colorado Holdings LLC Has $10.36 Million Holdings in CG Oncology, Inc. $CGON
Company News for Mar 2, 2026
CG Oncology GAAP EPS of -$2.08 beats by $0.09, revenue of $4.04M beats by $1.24M
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Mulay James | M-Exempt | 654 | $3.72 | 2026-03-16 |
| Mulay James | S-Sale | 1,310 | $63.50 | 2026-03-16 |
| Mulay James | M-Exempt | 1,310 | $12.59 | 2026-03-16 |
| Mulay James | M-Exempt | 654 | $3.72 | 2026-03-16 |
| Mulay James | M-Exempt | 1,310 | $12.59 | 2026-03-16 |